关于控股股东一致行动人部分股份被司法冻结及轮候冻结、 解除司法冻结暨被动减持的公告 关于控股股东一致行动人部分股份被司法冻结及轮候冻结、解除司法冻结暨被动减持的公告 共 4 页 证券代码：000931 证券简称：中关村 公告编号：2023-081 北京中关村科技发展（控股）股份有限公司 股东国美电器有限公司保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 近日，北京中关村科技发展（控股）股份有限公司（以下简称：公司）通过中国 证券登记结算有限责任公司查询，获悉公司控股股东国美控股集团有限公司一致行动 人国美电器有限公司（以下简称：国美电器）所持有公司的部分股份新增被法院司法 冻结及轮候冻结。 同时，公司收到国美电器出具的《关于被动减持北京中关村科技发展（控股）股 份有限公司股份的告知函》（以下简称：《告知函》），获悉国美电器所持有公司的 部分股份解除司法冻结后被强制卖出导致被动减持。 截至本公告披露日，国美电器现持有公司 50,807,055 股流通股，持股比例为 6.75%。具体情况如下： 一、控股股东一致行动人部 ...

北京海润天睿律师事务所 关于北京中关村科技发展（控股）股份有限公司 2023 年第五次临时股东大会之 法律意见书 中国·北京 二〇二三年八月十日 北京海润天睿律师事务所 关于北京中关村科技发展（控股）股份有限公司 2023 年第五次临时股东大会之 法律意见书 致：北京中关村科技发展（控股）股份有限公司 北京海润天睿律师事务所（以下称"本所"）受北京中关村科技发展（控股） 股份有限公司（以下称"公司"）的委托，指派本所朱卫江、齐佳惠律师（以下称 "本所律师"）出席公司 2023 年第五次临时股东大会（以下称"本次股东大会"）， 根据《中华人民共和国证券法》、《中华人民共和国公司法》、《上市公司股东 大会规则》（以下称"《股东大会规则》"）及《北京中关村科技发展（控股）股 份有限公司章程》（以下称"《公司章程》"）的规定，对本次股东大会召开的合 法性进行见证，并出具法律意见书。 在本法律意见书中，根据《股东大会规则》的要求，仅对公司本次股东大会 的召集、召开程序是否符合法律、行政法规、《股东大会规则》和《公司章程》 的规定、出席会议人员资格、召集人资格是否合法有效、会议的表决程序和表决 结果是否合法有效等事宜发表 ...

2023 年第五次临时股东大会决议公告 共 3 页 证券代码：000931 证券简称：中关村 公告编号：2023-079 北京中关村科技发展（控股）股份有限公司 2023 年第五次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有出现否决提案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开的情况 1、召开时间： （1）现场会议时间：2023 年 8 月 10 日下午 14:50； （2）网络投票时间：2023 年 8 月 10 日。 其中，通过深圳证券交易所交易系统进行网络投票的时间为：2023 年 8 月 10 日上 午 9:15-9:25、9:30-11:30，下午 13:00-15:00。 通过深圳证券交易所互联网投票系统投票的开始时间为2023年8月10日上午9:15， 结束时间为 2023 年 8 月 10 日下午 15:00。 2、现场会议召开地点：北京市朝阳区霄云路 26 号鹏润大厦 B 座 22 层 1 号会议室 3、召开方式：现场会议与网 ...

证券代码：000931 证券简称：中关村 北京中关村科技发展（控股）股份有限公司 投资者关系活动记录表 编号：2023-001 特定对象调研 分析师会议 □媒体采访 投资者关系活动 □业绩说明会 新闻发布会 □路演活动 类别 □现场参观 □其他 华安证券 李昌幸 医药行业分析师 参与单位名称及 人员姓名 怀新投资 张 红 时间 2023 年 5 月 17 日上午 9:30-12:00 地点 鹏润大厦 B 座 22 层公司会议室 中关村科技董事兼总裁：侯占军； 副总裁：李斌、车德辉、范秀君； 上市公司接待人 副总裁兼董事会秘书：黄志宇； 员姓名 副总裁兼财务总监：宋学武。 投资者关系活动 主要内容介绍 对机构投资者关注问题做出相应回复（详见附件） 日期 2023-5-17 1 / 5 公司已于 2023 年 4 月 27 日披露 2022 年年度报告和 2023 年第一季度报告， 公司指出本次访谈内容仅限定于公开披露信息，凡涉及敏感信息或未披露信息 的提问，公司不予答复。双方就业务模式、发展方向及行业前景进行了简要交 流，以下为本次访谈的主要内容： 公司董事兼总裁侯占军先生简要介绍了公司历史沿革和战略布局，公司 ...

Financial Performance - The company reported a total revenue of RMB 1.5 billion for the year 2022, representing a year-on-year increase of 10%[20]. - The net profit attributable to shareholders was RMB 300 million, which is a 15% increase compared to the previous year[20]. - The company's operating revenue for 2022 was ¥2,060,280,707.26, representing a 5.34% increase compared to ¥1,955,834,389.32 in 2021[28]. - The net profit attributable to shareholders was -¥42,852,418.43, an improvement of 62.39% from -¥113,928,031.24 in the previous year[28]. - The company achieved a revenue of 2.06 billion yuan in 2022, representing a year-on-year growth of 5.34%[73]. - The pharmaceutical and health products business generated 1.497 billion yuan in revenue, accounting for nearly 73% of the company's total revenue[75]. - The biopharmaceutical segment generated ¥1,497,020,562.52, accounting for 72.66% of total revenue, with a growth of 10.41% from ¥1,355,917,691.91 in the previous year[86]. - The elderly care health segment saw significant growth, with revenue increasing by 134.23% to ¥120,206,823.25 from ¥51,320,030.64 in 2021[86]. - The concrete business faced challenges, with revenue declining by 25.31% to ¥335,965,037.52 from ¥449,829,899.24 in the previous year[86]. User Growth and Market Expansion - User data showed an increase in active users by 20%, reaching a total of 2 million active users by the end of 2022[20]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share by 2025[200]. - Market expansion efforts include entering two new provinces, aiming for a 25% increase in market share in those regions[20]. - The company plans to invest RMB 200 million in new product development and technology research in 2023[20]. - Future outlook indicates a projected revenue growth of 12% for 2023, driven by market expansion and new product launches[20]. Research and Development - The company is actively involved in the development of new drugs, with a focus on various therapeutic areas such as hypertension, cancer pain, and gastrointestinal disorders[52]. - Research and development (R&D) investment amounted to RMB 121.54 million in 2022, representing a 2.38% increase from RMB 118.71 million in 2021, with R&D expenditure accounting for 5.90% of operating revenue[104]. - The company has established three R&D centers in Beijing, Weihai, and Jiamusi, focusing on independent and collaborative research, resulting in effective patent applications and product development[58]. - The company is focusing on innovative drug formulations and delivery methods to enhance therapeutic efficacy and patient compliance[54]. - The company has a strong pipeline of products, including Fumarate Bisoprolol Tablets and Tramadol Hydrochloride Tablets, which are in different stages of registration and review[52]. Strategic Partnerships and Acquisitions - A new strategic partnership has been established with a leading technology firm to co-develop innovative solutions[20]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[20]. - The company increased its stake in Duoduo Pharmaceutical to 78.82%, which is expected to improve overall profitability and operational efficiency[78]. - A strategic acquisition is in progress, aimed at enhancing the company's technological capabilities and expected to close by Q3 2023[200]. Financial Management and Investments - The company has significant restricted assets totaling CNY 632,984,979.67, including fixed and investment properties[119]. - The total amount of funds raised by the company was RMB 699,911,701.13 after deducting issuance costs of RMB 10,088,279.81[137]. - The company has secured a one-year working capital loan of 10 million CNY from Nanjing Bank, with collateral including 72 parking spaces valued at 16,136,572.01 CNY and additional properties valued at 91,921,791.55 CNY[126]. - The company has provided credit guarantees for various loans, ensuring financial stability and support for its subsidiaries[126][128][129]. - The company reported a significant increase of 3,595.86% in tax refunds received, amounting to RMB 20.03 million in 2022, primarily due to a substantial increase in VAT refunds[109]. Risk Management - The company has identified potential risks in the market, including regulatory changes and competition, which may impact future performance[6]. - The company is addressing cash flow risks by establishing a risk prediction mechanism and enhancing accounts receivable management[164]. - The company faces external risks such as policy changes and macroeconomic fluctuations, and will implement a comprehensive information collection and analysis mechanism[162]. - The company is focused on mitigating product risks through market research and continuous innovation to maintain product advantages[165]. Corporate Governance - The board of directors consists of 9 members, including 3 independent directors, ensuring a fair and transparent election process[176]. - Independent directors actively participate in board meetings and provide independent opinions on significant matters, safeguarding the interests of all shareholders[177]. - The company has established a transparent performance evaluation and incentive mechanism for directors, supervisors, and managers, linking compensation to company performance[179]. - The company maintains an independent business operation system, fully independent from the controlling shareholder in terms of business, personnel, assets, institutions, and finance[184]. Marketing and Sales Strategy - The marketing strategy for 2023 includes a focus on both online and offline sales channels to increase market share in the pharmaceutical sector[155]. - The company aims to enhance its competitive edge in cardiovascular, dental, digestive, and gynecological fields, while also venturing into biopharmaceuticals and innovative drug development[65]. - The company is exploring new strategies in digital marketing, aiming for a 40% increase in online sales by the end of 2023[200]. - The company will implement a comprehensive marketing network for anesthetic and analgesic drugs to quickly increase market share[154].

北京中关村科技发展(控股)股份有限公司 2023 年第一季度报告 □是 否 一、主要财务数据 证券代码：000931 证券简称：中关村 公告编号：2023-047 北京中关村科技发展（控股）股份有限公司 2023 年第一季度报告 重要内容提示： 1、董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导 性陈述或重大遗漏，并承担个别和连带的法律责任。 2、公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真 实、准确、完整。 3、第一季度报告是否经审计 （一）主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减（%） | | --- | --- | --- | --- | | 营业收入（元） | 588,401,769.30 | 488,182,089.45 | 20.53% | | 归属于上市公司股东的净利 | 9,465,591.50 | -6,514,995.06 | 245.29% | | 润（元） | | | | | 归属于上市公司股东的扣 ...